Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474459 | 1.00 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9945538 | 0.90 | SLC28A1 (0.80) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9946958 | 0.90 | SLC28A1 (0.80) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1867440 | 0.90 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1867441 | 0.89 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31543004 | 0.84 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6269325 | 0.84 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6269323 | 0.84 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20610932 | 0.84 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18464354 | 0.84 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071311-B2 | Antibodies having specificity for 2′-C-allyl nucleic acids | SIRNA THERAPEUTICS, INC. (US) | 2006-07-04 | — | — | US | claimed |
| US-7034009-B2 | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) | SIRNA THERAPEUTICS, INC. (US) | 2006-04-25 | — | — | US | claimed |
| JP-2005500025-A | — | — | 2005-01-06 | — | — | JP | claimed |
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | claimed |
| EP-1390385-A4 | NUCLEIC ACID BASED MODULATION OF FEMALE REPRODUCTIVE DISEASES AND CONDITIONS | SIRNA THERAPEUTICS INC (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040077565-A1 | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) | RIBOZYME PHARMACEUTICALS, INC. AND CHIRON. | 2004-04-22 | — | — | US | claimed |
| EP-1390385-A2 | NUCLEIC ACID BASED MODULATION OF FEMALE REPRODUCTIVE DISEASES AND CONDITIONS | Sirna Therapeutics, Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030228590-A1 | Antibodies having specificity for nucleic acids | SIRNA THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| WO-2002096927-A2 | RIBOZYME BASED TREATMENT OF FEMALE REPRODUCTIVE DISEASES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-12-05 | — | — | WO | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12208140-B2 | Targeted delivery to beta cells | THE BROAD INSTITUTE, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0866865-B1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | VIMRX HOLDINGS LTD (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0866865-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | Vimrx Holdings, Ltd. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997018312-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | VIMRX HOLDINGS, LTD. (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | SLC28A1 1787/4885SLC28A2 1441/4885SLC29A1 1254/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | SLC28A1 1240/4885SLC28A2 1183/4885SLC29A1 769/4885 |
| US-12208140-B2 | Targeted delivery to beta cells | IAPP, ZFR, ZC3H11A | SLC28A1 1201/4885SLC28A2 1478/4885SLC29A1 1974/4885 |
| US-20030228590-A1 | Antibodies having specificity for nucleic acids | DUT, NSUN3, DNASE1L3 | SLC28A1 320/4885SLC28A2 328/4885SLC29A1 19/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | SLC28A1 1201/4885SLC28A2 1478/4885SLC29A1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.